awmsg logo



pasireotide (Signifor®)


Reference No. 643

Publication date:
15/06/2016


Appraisal information

pasireotide (Signifor®) 20 mg powder and solvent for suspension for injection
pasireotide (Signifor®) 40 mg powder and solvent for suspension for injection
pasireotide (Signifor®) 60 mg powder and solvent for suspension for injection


Company: Novartis Pharmaceuticals UK Ltd
BNF category: Endocrine system
NMG meeting date: 20/01/2016
AWMSG meeting date: 18/05/2016
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 1316
Ministerial ratification: 10/06/2016

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Pasireotide (as pamoate) (Signifor®) is recommended as an option for use within NHS Wales for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with another somatostatin analogue.
Final Appraisal Recommendation (FAR)
Download
Clinician and Patient Involvement Group (CAPIG) Meeting Summary
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download